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ABSTRACT
Objective: Chronic total occlusion (CTO) is frequently found in coronary heart disease (CHD) with multivessel lesions. Patients with CTO are associated 
with an increased mortality rate. Management CTO requires specialized techniques, more resource utilization, and high cost. The progression of 
atherosclerosis can be prevented by controlling for risk factors. Monocyte to high-density lipoprotein ratio (MHR) is one of the new biomarkers used 
to assess the incidence of a major adverse cardiovascular event, the severity of coronary lesions, and the incidence of in-stent restenosis. This study 
was aimed to determine the role of MHR levels as a risk factor for the occurrence of CTO in CAD patients.
Methods: This research is a matched case–control located in Sanglah General Hospital from August 2017 until October 2017. This research consisted 
of 47 cases with CTO and 47 control without CTO. Case and control samples were adjusted by sex, age, and number of blood vessels involved in CAD.
Results: The cutoff value of MHR was also determined by analyzing the receiver operating curve. The optimal cut off point was 14.33 with sensitivity 
83% and specificity 80.9%. Bivariate analysis showed high MHR was found strongly associated with the risk of CTO in CHD patients with odds ratio 
(OR)=61; IK 95% (OR)=3.211–114.15; p≤0.001. Multivariate analysis showed that high levels of MHR were significantly associated with risk of CTO 
after other traditional risk factors such as hypertension, diabetes mellitus, dyslipidemia, and smoking were controlled with OR=20,306; 95% IK 
(OR)=6.05–68.05; p≤0.001.
Conclusion: High levels of MHR were significantly associated with the risk factor of CTO in CAD patients.
Keywords: Chronic total occlusion, Monocyte to HDL ratio, Coronary artery disease
INTRODUCTION
Patients with coronary heart disease (CHD) have high morbidity and 
mortality rates. Every year in America, 660,000 new cases of CHD are 
found and 305,000 cases of recurrent attacks are found [1]. In 2010, 
CHD was the cause of 80,000 deaths in the UK [2]. In 2016, there were 
35% of CHD cases from all cardiovascular cases handled at Pelayanan 
Jantung Terpadu (PJT) Sanglah Hospital Denpasar [3].
In the initial phase, CHD patients can be asymptomatic. Atherosclerotic 
plaques that continue to develop can rupture and cause thrombus 
blockage in coronary arteries. This can cause unstable angina, acute 
coronary syndrome, to sudden cardiac death. The development of 
atherosclerotic plaque together with fibrotic tissue and old thrombus 
can form chronic total occlusion (CTO) [4]. CTO is the progression 
of CHD accompanied by severe fibrosis and calcification tissue. 
CTO events are often found in CHD with complex lesions and have 
a prevalence rate of 12–20% [5]. In a study conducted in Texas, the 
United States found a 46% incidence of CTO cases in CHD patients [6]. 
The prevalence of CTO in CHD patients treated at PJT Sanglah Hospital 
Denpasar is 15% [3].
A prospective study of CHD risk factors found that monocytes have the 
strongest relationship of all white blood cell subtypes [7,8]. Monocytes 
or macrophages have an important role in the initiation and propagation 
of the atherosclerotic process. Monocytes have been shown to play a 
role in the early process of atherosclerotic plaque formation which is 
accelerated by different risk factors such as smoking, hypertension, 
hyperglycemia, and dyslipidemia [9]. Activated monocytes and damaged 
endothelium can trigger the overexpression of adhesion molecules and 
pro-inflammatory cytokines [10].
In contrast, high-density lipoprotein (HDL) can reduce the accumulation 
of macrophages and prevent oxidized cholesterol from entering the 
arterial wall. This process is mediated by the ability of HDL to reduce 
the expression of adhesion molecules and chemotaxis molecules on 
the surface of monocytes or macrophages which causes the expression 
of CD14 on monocytes to decrease [11]. This causes HDL to resist the 
inflammatory and oxidation processes caused by monocytes. In the 
case of patients who have low HDL levels, it will reduce the protective 
effect against atherosclerosis resulting in an increased risk for vascular 
disorders [12]. This is supported by research conducted by the multi-
ethnic study of atherosclerosis found that patients with low HDL values 
have a higher risk of developing CHD than patients with optimal lipid 
profiles [13]. HDL concentrations also decrease during the inflammatory 
process. In the acute phase of inflammation, HDL becomes unstable and 
loses its protective ability [14].
One of the pathogenesis of atherosclerosis is an inflammatory process. 
The pro-inflammatory effects of monocytes and the anti-inflammatory 
effects of HDL can be used as markers of the body’s inflammatory 
status. At present, monocyte to HDL ratio (MHR) can be used as a new 
predictive marker and prognosis in cardiovascular disease. Both of 
these tests are easily available in the laboratory and are routine checks 
performed on CHD patients.
Based on the background described above, research will be conducted 
on the role of high MHR as a risk factor in patients with CTO. This 
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research was conducted because there are no studies that examined the 
increase in monocytes and decreased levels of HDL indicated by high 
MHR values as a risk factor in patients with CTO.
METHODS
This study is a retrospective case–control study to prove the role of high 
MHR as a risk factor for CTO events in CHD patients. Patients with CHD 
are grouped into two groups: CTO patients with high MHR and CTO 
sufferer with not high MHR according to the results of the cut point 
values in the receiver operating curve (ROC) curve analysis. All patients 
receive treatment management according to the European Society of 
Cardiology guidelines. The location and time of the study were in the 
cardiac catheterization laboratory of the integrated heart service (PJT) 
and Sanglah Denpasar Hospital medical record unit, carried out from 
August 2017 until the number of samples was reached. This study has 
received a Certificate of Eligibility for Ethics from the Ethics Commission 
of the Faculty of Medicine of Udayana University with Protocol number: 
2017.02.1.1065. The sample is determined consecutively, i.e., taking the 
sample by specifying subjects who meet the criteria as a research sample 
until it reaches the required number of samples, which is by following 
the sample calculation of 47 people in each group, with inclusion 
criteria: All CHD patients with CTO who perform angiographic actions 
coronary hospital, and exclusion criteria: Patients with the following 
criteria: Malignancy, septic patients, patients with liver disorders, 
thyroid dysfunction, chronic kidney failure, autoimmune disease, CHD 
patients with in-stent restenosis (ISR), and finally incomplete.
RESULTS
To stratify the MHR value, it is necessary to limit the value obtained by 
making a ROC curve. Based on the analysis of the ROC curve obtained 
a threshold value in expressing high MHR levels in predicting the 
incidence of CTO in CHD patients. The threshold value obtained was 
14.33 with an area under the curve (AUC) 0.926 (p<0.001), a sensitivity 
of 83% and a specificity of 80.9%. An illustration of the characteristics 
of the threshold study population obtained from the ROC curve is 
shown in Fig. 1.
Odds ratio (OR) values will be calculated by cross-tabulating the case–
control pairs as Table 2.
Table 2 shows a significant relationship between high MHR and the 
risk of CTO in CHD with a risk of 61 times compared to patients with 
low MHR (OR=61; 95% confidence interval [CI] (OR)=3.211–114.15; 
p≤0.001). This shows a significant MHR as a risk factor for CTO events 
in CHD patients.
DISCUSSION
Some traditional risk factors influence the progression of atherosclerosis 
such as diabetes, smoking, dyslipidemia, hypertension, and obesity. In 
this study, it was found that smoking, hypertension, and obesity were 
not significantly different between the case and control groups. Diabetes 
and dyslipidemia are risk factors that have a significant influence on 
CTO with p=0.032 and p≤0.001. This study found that 46.8% of patients 
with diabetes mellitus (DM) suffer from CTO (Table 1). Similar results 
were found in multicenter studies in Canada that the incidence of DM 
with CTO was 34% [15].
This can occur because in patients with DM, complex inflammatory 
processes and endothelial dysfunction occur making it easier to process 
atherothrombosis which can play a role in the process of restenosis and 
new coronary lesions [16]. In this study, almost the majority of CTO 
patients who had dyslipidemia were 95.7%. In the European registry 
of CTO data obtained that dyslipidemia is the most common risk factor 
of 74.9% [17]. Dyslipidemia acts as an inhibitor of arteriogenesis 
which will worsen the process of ischemia. The accumulated 
cholesterol is a component of arterial plaque which is a pathogenesis 
of atherosclerosis [18].
ROC curve analysis
In this study, the AUC value for MHR obtained in this study was 0.926 
with a standard error of 0.0025; (95% CI=0.878–0.974), p<0.001 
sensitivity 83% and specificity 80.9%. In this study, the MHR cut value 
Fig. 1: Characteristics of the threshold study population
Table 2: Cross tabulation between MHR variables and CTO 
variables
Groups Control Total
High MHR Low MHR
Case
High MHR 9 30.5 39
Low MHR 0.5 8 8
Total 9 38 47
OR=61; CI 95% (OR) = 3.211–114.15; P≤0.001. OR: Odds ratio, CTO: Chronic 
total occlusion, MHR: Monocyte to high-density lipoprotein ratio, CI: Confidence 
interval
Table 1: Description of research subject characteristics based 
on case and control groups
Variable Case (n=47) Control (n=47)
Age (years) 58.23±SD 8.422 57.70±SD 7.953
18–65 (%) 37 (78.7) 39 (83)
66–79 (%) 10 (21.3) 8 (17)
Sex
Male n (%) 37 (78.7) 37 (78.7)
Female n (%) 10 (21.3) 10 (21.3)
Vessel amount
Single vessel (%) 3 (6.4) 3 (6.4)
Multi vessel (%) 44 (93.6) 44 (93.6)
Traditional risk factor
DM type 2
Yes 22 (46.8) 12 (25.5)
No 25 (53.2) 35 (74.5)
Dyslipidemia
Yes 45 (95.7) 24 (51.5)
No 2 (4.3) 23 (48.9)
Smoking
Yes 16 (34) 21 (44.7)
No 31 (66) 26 (55.3)
Hypertension
Yes 35 (74.5) 33 (70.2)
No 12 (25.5) 14 (29.8)
BMI
Obese 4 (8.5) 3 (6.4)
Non obese 43 (91.5) 44 (93.6)
Statin therapy 47 (100) 47 (100)
DM: Diabetes mellitus, BMI: Body mass index
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was 14.33. Almost the same value was obtained in previous studies that 
used a cut value for high MHR of 14.1 which was used to predict the 
incidence of ISR in patients undergoing BMS stents [19]. In the MHR 
study to predict the incidence of mortality in patients with ACS who 
performed a primary PCI using a cutoff value of 17.1 [20].
Relationship of high MHR as a predictor of CTO events in CHD 
patients
The results of this study show a significant relationship between MHR 
and the risk of CTO changes in CHD. In this study showed that a high 
MHR has an OR of 61 (OR=61; 95% CI [OR]=3.211–114.15; p≤0.001). 
This shows CHD patients who have MHR values who have a high risk of 
61 times higher than CTO. The results taken by MHR are submitted as a 
factor that lends CTO.
The mechanism underlying MHR as a risk factor for CTO is the inflammatory 
process caused by monocyte activation and the anti-inflammatory effect 
possessed by HDL. The initial stage of the process of atherosclerosis is 
monocyte activation. In the early stages of the atherosclerosis process in 
endothelial dysfunction. After endothelial dysfunction, monocytes and 
T lymphocytes attach to the endothelium which then migrates into the 
subendothelial chamber. This interaction will also cause overexpression 
of adhesion molecules and pro-inflammatory cytokines such as 
intracellular-1 adhesion molecules, cell-1 molecule adhesion molecules, 
and chemotactic ligand-1 monocyte proteins [21].
Monocytes then turn into macrophages which can carry out phagocytosis 
of oxidized low-density lipoprotein (LDL) cholesterol molecules through 
the SR-A and CD-36 scavenger receptors [22]. The foam cell will then 
form fat bubbles which will secrete pro-inflammatory cytokines which 
will improve the local inflammatory response in the lesion area, the 
metalloproteinase matrix, the tissue factor will turn into a local matrix, 
and the growth factor will stimulate the replication of smooth muscle 
cells. Increased metalloproteinase will cause internal elastic disruption, 
causing plaque prone to rupture. Tissue factor is located in an area rich 
in macrophages in the necrotic nucleus of plaque. Tissue excretion and 
contact with blood circulation will cause thrombus formation [23]. 
This thrombus will join the granulation tissue and repair infiltration 
by smooth muscle cells by collagen and proteoglycan deposition. This 
process is then followed by the formation of fibrous plaques that are 
returned calcified which develops into CTO [24-26].
HDL works in preventing direct responses to activated monocytes and 
repairing adhesion molecules in endothelial cells, thereby preventing the 
recruitment of new monocytes and indirectly completing macrophage 
collection on blood transfer [27]. The important function of HDL is as 
an antioxidant through oxidation of free radicals in LDL, activated lipid 
hydroperoxides and through reductions that inhibit the redox-active of 
apolipoprotein A-I in favor of inactive hydroxides [28]. Furthermore, HDL 
can increase the expression of nitric oxide synthase in endothelial tissue 
and cause vasorelaxation. Low HDL levels will reduce the protective effect 
against atherosclerosis and are often associated with a worse prognosis.
This study found that patients who had significantly high MHR as 
predictors of CTO events in CHD patients. It can be explained that a high 
MHR is a sign of a high inflammatory and oxidant process while the 
protective effect on atherogenic is decreased. This is very important as 
the initial process and progression of atherosclerosis. This progressivity 
will increase the severity of coronary artery lesions.
CONCLUSION AND SUGGESTION
This research has proven that high MHR as a risk factor in the occurrence 
of CHD on CTO. The decrease in HDL is a component of the high MHR 
value so that it can be a target for therapy in the management of CHD to 
prevent the progression of atherosclerosis.
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